Insider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) Insider Sells 2,937 Shares of Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) insider Carole Ho sold 2,937 shares of the stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total transaction of $39,884.46. Following the sale, the insider directly owned 217,391 shares in the company, valued at $2,952,169.78. This represents a 1.33% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Carole Ho also recently made the following trade(s):

• On Wednesday, August 13th, Carole Ho sold 806 shares of Denali Therapeutics stock. The shares were sold at an average price of $14.64, for a total transaction of $11,799.84.

Denali Therapeutics Stock Performance

Shares of Denali Therapeutics stock opened at $14.70 on Friday. The firm has a market capitalization of $2.15 billion, a P/E ratio of -5.25 and a beta of 1.36. Denali Therapeutics Inc. has a 52 week low of $10.57 and a 52 week high of $33.33. The company has a quick ratio of 9.56, a current ratio of 10.27 and a debt-to-equity ratio of 0.01. The firm’s 50 day moving average is $14.30 and its two-hundred day moving average is $15.36.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.02. During the same quarter in the previous year, the business earned ($0.59) earnings per share. Research analysts forecast that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Hedge Funds Weigh In On Denali Therapeutics

A number of hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Denali Therapeutics by 15.5% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,612 shares of the company’s stock worth $79,000 after acquiring an additional 753 shares during the last quarter. Ameritas Investment Partners Inc. grew its position in shares of Denali Therapeutics by 7.4% during the second quarter. Ameritas Investment Partners Inc. now owns 13,522 shares of the company’s stock worth $189,000 after acquiring an additional 930 shares during the last quarter. Knights of Columbus Asset Advisors LLC grew its position in shares of Denali Therapeutics by 2.7% during the first quarter. Knights of Columbus Asset Advisors LLC now owns 40,275 shares of the company’s stock worth $548,000 after acquiring an additional 1,058 shares during the last quarter. Sterling Capital Management LLC grew its position in shares of Denali Therapeutics by 589.9% during the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company’s stock worth $36,000 after acquiring an additional 1,516 shares during the last quarter. Finally, E Fund Management Co. Ltd. lifted its holdings in shares of Denali Therapeutics by 12.8% during the second quarter. E Fund Management Co. Ltd. now owns 13,612 shares of the company’s stock worth $190,000 after purchasing an additional 1,543 shares during the period. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on DNLI shares. Bank of America reduced their target price on shares of Denali Therapeutics from $28.00 to $27.00 and set a “buy” rating on the stock in a report on Monday, May 19th. TD Cowen raised shares of Denali Therapeutics to a “strong-buy” rating in a report on Monday, July 28th. William Blair raised shares of Denali Therapeutics to a “strong-buy” rating in a report on Thursday, April 24th. Wedbush reduced their target price on shares of Denali Therapeutics from $32.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, May 7th. Finally, Robert W. Baird reduced their target price on shares of Denali Therapeutics from $30.00 to $29.00 and set an “outperform” rating on the stock in a report on Thursday, May 8th. One analyst has rated the stock with a hold rating, thirteen have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $33.85.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.